15,952 results
Search Results
2. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
- Author
-
Gomes F, Wong M, Battisti NML, Kordbacheh T, Kiderlen M, Greystoke A, and Luciani A
- Subjects
- Antineoplastic Agents administration & dosage, Carcinoma, Non-Small-Cell Lung mortality, Clinical Trials as Topic, Humans, Immune Checkpoint Inhibitors adverse effects, Immunosenescence, Lung Neoplasms mortality, Carcinoma, Non-Small-Cell Lung therapy, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy methods, Lung Neoplasms therapy, Radioimmunotherapy methods
- Abstract
Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.
- Published
- 2020
- Full Text
- View/download PDF
3. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.
- Author
-
Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, and Goldberg SN
- Subjects
- Humans, Societies, Medical, Immunotherapy methods, Medical Oncology methods, Neoplasms diagnostic imaging, Neoplasms therapy, Radiology, Interventional methods
- Abstract
Interventional oncology is a subspecialty field of interventional radiology that addresses the diagnosis and treatment of cancer and cancer-related problems by using targeted minimally invasive procedures performed with image guidance. Immuno-oncology is an innovative area of cancer research and practice that seeks to help the patient's own immune system fight cancer. Both interventional oncology and immuno-oncology can potentially play a pivotal role in cancer management plans when used alongside medical, surgical, and radiation oncology in the care of cancer patients., (© RSNA, 2019.)
- Published
- 2019
- Full Text
- View/download PDF
4. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
- Author
-
Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, Franquet T, Blijlevens NMA, and Maertens JA
- Subjects
- Hematologic Neoplasms immunology, Hematologic Neoplasms metabolism, Humans, Infections pathology, Prognosis, Hematologic Neoplasms drug therapy, Immunotherapy adverse effects, Infections etiology, Molecular Targeted Therapy adverse effects
- Abstract
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed.
- Published
- 2019
- Full Text
- View/download PDF
5. AllergoOncology - the impact of allergy in oncology: EAACI position paper.
- Author
-
Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, Levi-Schaffer F, Meshcheryakova A, Mechtcheriakova D, Mekori Y, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J, Spicer JF, Siccardi AG, Spillner E, Turner MC, Untersmayr E, Vangelista L, and Karagiannis SN
- Subjects
- Antibodies, Humans, Immunoglobulin E immunology, Immunologic Surveillance, Immunotherapy trends, Neoplasms therapy, Th2 Cells immunology, Hypersensitivity immunology, Immunotherapy methods, Neoplasms immunology
- Abstract
Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment., (© 2016 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
6. New immune cell engagers for cancer immunotherapy.
- Author
-
Fenis A, Demaria O, Gauthier L, Vivier E, and Narni-Mancinelli E
- Subjects
- Humans, Animals, Myeloid Cells immunology, Neoplasms immunology, Neoplasms therapy, Immunotherapy methods, Killer Cells, Natural immunology, T-Lymphocytes immunology
- Abstract
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers - antibodies engineered to redirect T cells to recognize and kill cancer cells - for the treatment of haematological malignancies. However, the field still faces several challenges to develop agents that are consistently effective in a majority of patients and cancer types, such as optimizing drug dose, overcoming treatment resistance and improving efficacy in solid tumours. A new generation of T cell-targeted molecules was developed to tackle these issues that are potentially more effective and safer. In addition, agents designed to engage the antitumour activities of other immune cells, including natural killer cells and myeloid cells, are showing promise and have the potential to treat a broader range of cancers., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
7. Save £5 when you spend £25 at Holland & Barrett with your Mirror; Put a spring in your step with the iconic UK healthcare brand Holland & Barrett and save £5 when you spend £25 or more in store starting inside your paper on Tuesday 7 May
- Subjects
Holland and Barrett ,Immunotherapy ,Skin care products ,General interest ,News, opinion and commentary - Abstract
Byline: By, Caroline Topping Get Spring ready with everything you need to get your skin and immune system boosted for the warmer weather with a great offer from Holland and [...]
- Published
- 2024
8. Heritable and spatial immunogenic traits co-predict the efficacy of immunotherapy in kidney cancer.
- Subjects
- Humans, Kidney Neoplasms immunology, Kidney Neoplasms therapy, Kidney Neoplasms genetics, Immunotherapy
- Published
- 2024
- Full Text
- View/download PDF
9. Studying paired patient tissue and blood enables insights into immunotherapy toxicity.
- Subjects
- Humans, Neoplasms immunology, Neoplasms therapy, Neoplasms drug therapy, Immunotherapy adverse effects
- Published
- 2024
- Full Text
- View/download PDF
10. Mineralized bacteria as an immunotherapy agent against various cancer types.
- Subjects
- Humans, Bacteria, Animals, Immunotherapy methods, Neoplasms therapy, Neoplasms immunology
- Published
- 2024
- Full Text
- View/download PDF
11. Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma.
- Subjects
- Humans, Animals, Mice, Melanoma genetics, Melanoma therapy, Melanoma immunology, Melanoma drug therapy, Mutation, DNA, Mitochondrial genetics, Immunotherapy methods
- Published
- 2024
- Full Text
- View/download PDF
12. Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper
- Author
-
Hong Qin, Changqiao You, Feng Yan, Kefang Tan, Changgen Xu, Rui Zhao, Marlene Davis Ekpo, and Songwen Tan
- Subjects
natural killer (NK) cells ,immunosenescence ,immunotherapy ,cancer ,chemotherapy ,biotherapeutics ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2022
- Full Text
- View/download PDF
13. HCW Biologics announces new paper on treating aging-associated diseases
- Subjects
Immunotherapy ,Pancreatic cancer ,Business ,News, opinion and commentary - Abstract
HCW Biologics published a pivotal scientific paper in Aging Cell entitled, 'Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice,' with Dr. Hing Wong, the Company's [...]
- Published
- 2023
14. Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research
- Subjects
Oncology, Experimental ,Viral antibodies ,Immunotherapy ,Cancer -- Research ,Antibodies ,Business ,News, opinion and commentary - Abstract
SHANGHAI and HONG KONG, March 19, 2024 /PRNewswire/ -- Antengene Corporation Limited ('Antengene' SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or [...]
- Published
- 2024
15. Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper.
- Author
-
Chan, Wing-Lok, Marinho, Joana, Chavarri-Guerra, Yanin, Hincapie-Echeverri, Jacobo, Velasco, Rogelio N., Akagunduz, Baran, Roy, Mukul, Kwong, Wing Tung Gobby, Wu, Wing-Fong, Battisti, Nicolò Matteo Luca, and Soto-Perez-de-Celis, Enrique
- Abstract
Breast cancer is the most common type of cancer affecting women worldwide and its risk increases with age. Compared with other breast cancer subtypes, triple negative breast cancer (TNBC) behaves more aggressively, with earlier relapses and poorer survival outcomes. Although the incidence of TNBC decreases with age, it still affects about 10% of older women with breast cancer. The management of TNBC in older patients is particularly challenging as chemotherapy is the main treatment choice in both early and advanced diseases and older patients are often prone to increased treatment-related toxicities. This review highlights the specific considerations in this vulnerable group of patients and summarizes the current evidence for TNBC management in older adults from early to late stage of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper.
- Author
-
Guven, Deniz Can, Martinez-Cannon, Bertha Alejandra, Testa, Giuseppe Dario, Martins, Janine Capobiango, Velasco, Rogelio N., Kalsi, Tania, and Gomes, Fabio
- Abstract
Immune checkpoint inhibitors (ICIs) became a treatment option in most tumor types and improved survival in patients with cancer in the last decade. Older patients with cancer are underrepresented in the pivotal clinical trials with ICIs. Older patients with cancer often have significant comorbidities and geriatric syndromes like frailty, which can complicate cancer care and treatment decisions. Frailty is among the most prevalent geriatric syndromes in patients with cancer and could lead to inferior survival and a higher risk of complications in patients treated with chemotherapy. However, the effect of frailty on the efficacy and safety of ICIs is understudied. This review focuses on the available evidence regarding the association between frailty and ICI efficacy and safety. Although the survival benefits of ICIs have generally been shown to be independent of age, the available real-world data has generally suggested higher rates of immune-related adverse events (irAEs) and treatment discontinuation in older patients. While international organizations recommend conducting a comprehensive geriatric assessment CGA to assess and address frailty before the start of anti-cancer therapies, an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher is frequently used in clinical practice as synonymous with frailty, albeit with significant limitations. The available data has generally demonstrated diminished ICI efficacy in patients with an ECOG 2 or higher compared to patients with better performance status, while the incidence of high-grade irAEs were similar. Whilst evidence regarding outcomes with ICI in older patients and in those with sub-optimal performance status is growing, there is very limited data specifically evaluating the role of frailty with ICIs. These studies found a shortened overall survival, yet no evidence of a lower response rate to ICIs. These patients experienced more AEs, but they did not necessarily have a higher incidence of irAEs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Symptom clusters and network analysis of patients with intermediate and advanced liver cancer treated with targeted immunotherapy.
- Author
-
Chen M, Li S, Jin G, Li R, Qi Z, and He Y
- Subjects
- Humans, Male, Middle Aged, Female, Cross-Sectional Studies, China, Aged, Adult, Severity of Illness Index, Quality of Life, Surveys and Questionnaires, Symptom Assessment methods, Liver Neoplasms therapy, Immunotherapy methods
- Abstract
Background: This study aims to identify symptom clusters in patients with intermediate and advanced liver cancer receiving targeted immunotherapy, focusing on core and bridge symptoms to establish a foundation for precise symptom management., Methods: This study used a cross-sectional survey and utilized convenience sampling from May 2023 to January 2024 at a third-class hospital in Shanghai, China. The severity of symptoms in liver cancer patients during treatment was evaluated using the Memorial Symptom Assessment Scale. Network analysis was employed to depict the interrelation of symptom clusters and identify core and bridge symptoms., Results: The symptoms were classified by severity into five clusters: oral, gastrointestinal, fatigue-related, body image, and pain-sleep. Within the symptom network, the core symptoms were pain, "I don't look like myself," and nausea, while the critical bridge symptoms included pain, itching, and feeling bloated. The strongest connections were observed between nausea and vomiting, followed by taste changes and dry mouth, as well as weight loss and "I don't look like myself.", Conclusion: In patients receiving targeted immunotherapy for intermediate and advanced liver cancer, multiple symptoms can emerge simultaneously, forming interconnected clusters. By identifying and intervening in core and bridge symptoms, personalized management strategies can be developed to relieve other symptoms and disrupt connections between symptom clusters, thereby enhancing symptom management efficacy. This study has significant clinical and research implications, offering new insights to improve patients' quality of life and treatment outcomes., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
18. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy.
- Author
-
Rees MJ and Kumar S
- Subjects
- Humans, Risk Factors, Prognosis, Multiple Myeloma genetics, Multiple Myeloma therapy, Multiple Myeloma diagnosis, Immunotherapy
- Abstract
Multiple myeloma (MM) exhibits significant heterogeneity in its presentation, genetics, and treatment response. Despite therapeutic advances, some patients continue to relapse early (ER, <18-months) and rapidly cycle through therapies. Myriad prognostic factors have been identified and incorporated into risk stratification models; however, these produce discordant, often three-tiered outputs that fail to identify many patients destined for ER. Treatment strategies are increasingly focused on disease biology and trials enriched for high-risk (HR)MM, but consensus on the minimum required testing and a succinct, specific, and clinically meaningful definition for HRMM remains elusive. We review the risk-factors, definitions, and future directions for HRMM., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
19. Exploiting bacteria for cancer immunotherapy.
- Author
-
Kwon SY, Thi-Thu Ngo H, Son J, Hong Y, and Min JJ
- Subjects
- Humans, Microbiota immunology, Neoplasms therapy, Neoplasms immunology, Neoplasms microbiology, Immunotherapy methods, Tumor Microenvironment immunology, Bacteria immunology
- Abstract
Immunotherapy has revolutionized the treatment of cancer but continues to be constrained by limited response rates, acquired resistance, toxicities and high costs, which necessitates the development of new, innovative strategies. The discovery of a connection between the human microbiota and cancer dates back 4,000 years, when local infection was observed to result in tumour eradication in some individuals. However, the true oncological relevance of the intratumoural microbiota was not recognized until the turn of the twentieth century. The intratumoural microbiota can have pivotal roles in both the pathogenesis and treatment of cancer. In particular, intratumoural bacteria can either promote or inhibit cancer growth via remodelling of the tumour microenvironment. Over the past two decades, remarkable progress has been made preclinically in engineering bacteria as agents for cancer immunotherapy; some of these bacterial products have successfully reached the clinical stages of development. In this Review, we discuss the characteristics of intratumoural bacteria and their intricate interactions with the tumour microenvironment. We also describe the many strategies used to engineer bacteria for use in the treatment of cancer, summarizing contemporary data from completed and ongoing clinical trials. The work described herein highlights the potential of bacteria to transform the landscape of cancer therapy, bridging ancient wisdom with modern scientific innovation., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
20. Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper
- Author
-
Battisti, Nicolò Matteo Luca, Liposits, Gabor, De Glas, Nienke Aafke, Gomes, Fabio, Baldini, Capucine, and Mohile, Supriya
- Published
- 2020
- Full Text
- View/download PDF
21. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
- Author
-
Martin S. Weber, Stefan Bittner, Claudio Gobbi, Hayrettin Tumani, Renaud Du Pasquier, Fedor Heidenreich, Ralf A. Linker, Frank Weber, Michael Platten, Martin Stangel, Andrew T. Chan, Heinz Wiendl, Olaf Hoffmann, Thomas Berger, Christian Enzinger, die Multiple Sklerose Therapie Konsensus Gruppe, Elisabeth Fertl, Mathias Mäurer, Orhan Aktas, Uwe K. Zettl, Ralf Gold, Boris Kallmann, Christoph Kleinschnitz, Florian Deisenhammer, Fritz Leutmezer, Jan D. Lünemann, Volker Limmroth, Zoë R. Hunter, Klaus Gehring, Aiden Haghikia, Verena I. Leussink, Franziska Di Pauli, Martin Berghoff, Michael Guger, Luisa Klotz, Tobias Derfuss, Tjalf Ziemssen, Stephan Schmidt, Uta Meyding-Lamadé, Hans-Peter Hartung, Sven G. Meuth, Frauke Zipp, Karl Baum, Achim Gass, Peter Rieckmann, Adam Czaplinski, Norbert Goebels, and Andreas Lutterotti
- Subjects
0301 basic medicine ,Central Nervous System ,medicine.medical_specialty ,Early therapeutic intervention ,Neurology ,Consensus ,Multiple Sclerosis ,Disease ,Guideline ,Behandlungsempfehlung ,03 medical and health sciences ,0302 clinical medicine ,Germany ,medicine ,Humans ,Intensive care medicine ,Leitlinie ,business.industry ,Multiple sclerosis ,Psychosomatic medicine ,General Medicine ,medicine.disease ,Autoimmune-mediated disease ,Immuntherapie ,Europe ,Psychiatry and Mental health ,030104 developmental biology ,Position paper ,Konsensuspapiere ,Neurology (clinical) ,Neurosurgery ,Psychopharmacology ,Immunotherapy ,business ,Treatment recommendation ,030217 neurology & neurosurgery ,Autoimmunerkrankung ,Frühe Therapieintervention - Abstract
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).Die Multiple Sklerose ist eine komplexe, autoimmun vermittelte Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie axonalen/neuronalen Schaden. Die Zulassung verschiedener verlaufsmodifizierender Therapien und unser verbessertes Verständnis der Krankheitsmechanismen und -entwicklung in den letzten Jahren haben die Prognose und den Verlauf der Erkrankung deutlich verändert. Diese Aktualisierung der Behandlungsempfehlung der Multiple Sklerose Therapie Konsensus Gruppe konzentriert sich auf die wichtigsten Empfehlungen für verlaufsmodifizierende Therapien der Multiplen Sklerose im Jahr 2021. Unsere Empfehlungen basieren auf aktuellen wissenschaftlichen Erkenntnissen und gelten für diejenigen Medikamente, die in weiten Teilen Europas, insbesondere in den deutschsprachigen Ländern (Deutschland, Österreich, Schweiz), zugelassen sind.
- Published
- 2021
22. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.
- Author
-
Sorbye, Halfdan, Grande, Enrique, Pavel, Marianne, Tesselaar, Margot, Fazio, Nicola, Reed, Nicholas Simon, Knigge, Ulrich, Christ, Emanuel, Ambrosini, Valentina, Couvelard, Anne, and Tiensuu Janson, Eva
- Subjects
- *
NEUROENDOCRINE tumors , *PROGNOSIS , *THERAPEUTICS , *OVERALL survival , *SURVIVAL rate , *MERKEL cell carcinoma , *IMMUNOTHERAPY - Abstract
This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐to‐date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. These recommendations aim to pave the road for more standardized care for our patients resulting in improved outcomes. Prognosis is generally poor for digestive NEC, most are advanced at diagnosis and median survival in metastatic disease is 11–12 months. Surgery can be of benefit for localized disease after extensive preoperative imaging. Carboplatin in combination with etoposide is recommended as first‐line treatment for metastatic disease. Irinotecan with fluoropyrimidines has the best evidence as second‐line treatment. Immunotherapy plays a minor role in biomarker‐unselected patients. Molecular profiling if available is encouraged to identify new targets. More prospective clinical trials are highly needed to fulfil the unmet needs in this field, especially on new predictive and prognostic biomarkers and to improve survival of patients with advanced disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. A Carbon-Caged Rhodamine Generating Nitrosoperoxycarbonate for Photoimmunotherapy.
- Author
-
Yin L, Zhao B, Zhou J, Huang Y, Ma H, Zhou T, Mou J, Min P, Chen J, Ge G, Qian X, Luo X, and Yang Y
- Subjects
- Animals, Mice, Phototherapy, Cell Line, Tumor, Humans, Molecular Structure, Fluorescent Dyes chemistry, Immunotherapy, Rhodamines chemistry, Carbon chemistry
- Abstract
Photoimmunotherapy is a promising cancer treatment modality. While potent 1-e
- oxidative species are known to induce immunogenic cell death (ICD), they are also associated with unspecific oxidation and collateral tissue damage. This difficulty may be addressed by post-generation radical reinforcement. Namely, non-oxidative radicals are first generated and subsequently activated into powerful oxidative radicals to induce ICD. Here, we developed a photo-triggered molecular donor (NPCD565) of nitrosoperoxycarbonate (ONOOCO2 ), the first of its class to our knowledge, and further evaluated its feasibility for immunotherapy. Upon irradiation of NPCD565 by light within a broad spectral region from ultraviolet to red, ONOOCO- ), the first of its class to our knowledge, and further evaluated its feasibility for immunotherapy. Upon irradiation of NPCD565 by light within a broad spectral region from ultraviolet to red, ONOOCO2 - , and its donor (NPCD565) has broad potential for photo-immunotherapy of cancer.2 - generation. Upon photolysis of NPCD565 in 4T1 cells, damage-associated molecular patterns (DAMPs) indicative of ICD were observed and confirmed to exhibit immunogenicity by induced maturation of dendritic cells. In vivo studies with a bilateral tumor-bearing mouse model showcased the potent tumor-killing capability of NPCD565 of the primary tumors and growth suppression of the distant tumors. This work unveils the potent immunogenicity of ONOOCO2 - , and its donor (NPCD565) has broad potential for photo-immunotherapy of cancer., (© 2024 Wiley-VCH GmbH.)- Published
- 2024
- Full Text
- View/download PDF
24. Lymphatic vessels in the age of cancer immunotherapy.
- Author
-
Karakousi T, Mudianto T, and Lund AW
- Subjects
- Humans, Animals, Immunologic Surveillance, Tumor Microenvironment immunology, Tertiary Lymphoid Structures immunology, Lymphangiogenesis, Lymphatic Vessels immunology, Neoplasms therapy, Neoplasms immunology, Immunotherapy methods
- Abstract
Lymphatic transport maintains homeostatic health and is necessary for immune surveillance, and yet lymphatic growth is often associated with solid tumour development and dissemination. Although tumour-associated lymphatic remodelling and growth were initially presumed to simply expand a passive route for regional metastasis, emerging research puts lymphatic vessels and their active transport at the interface of metastasis, tumour-associated inflammation and systemic immune surveillance. Here, we discuss active mechanisms through which lymphatic vessels shape their transport function to influence peripheral tissue immunity and the current understanding of how tumour-associated lymphatic vessels may both augment and disrupt antitumour immune surveillance. We end by looking forward to emerging areas of interest in the field of cancer immunotherapy in which lymphatic vessels and their transport function are likely key players: the formation of tertiary lymphoid structures, immune surveillance in the central nervous system, the microbiome, obesity and ageing. The lessons learnt support a working framework that defines the lymphatic system as a key determinant of both local and systemic inflammatory networks and thereby a crucial player in the response to cancer immunotherapy., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
25. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
- Author
-
Denise Hilfiker-Kleiner, Michael Hallek, Roman Pfister, Tienush Rassaf, Diana Lüftner, Johann Bauersachs, Ulrich Neudorf, Lorenz H. Lehmann, Stephan von Haehling, Oliver J. Müller, Johannes Backs, Matthias Totzeck, Andreas Hochhaus, and Carsten Bokemeyer
- Subjects
medicine.medical_specialty ,Side effect ,Cancer therapy ,medicine.medical_treatment ,Medizin ,Antineoplastic Agents ,030204 cardiovascular system & hematology ,German ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Consensus Paper ,Risk Factors ,Internal medicine ,Germany ,Neoplasms ,medicine ,Chemotherapy ,Humans ,Adverse effect ,Cardiotoxicity ,Hematology ,Radiotherapy ,business.industry ,General Medicine ,Survivorship programs ,Combined Modality Therapy ,language.human_language ,Radiation therapy ,Cardio-oncology ,Cardiovascular Diseases ,030220 oncology & carcinogenesis ,language ,Cardiology ,Quality of Life ,Immunotherapy ,Cardiology and Cardiovascular Medicine ,business - Abstract
The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.
- Published
- 2020
26. Allergen Content of Therapeutic Preparations for Allergen-Specific Immunotherapy of European Paper Wasp Venom Allergy.
- Author
-
Grosch, Johannes, Lesur, Antoine, Kler, Stéphanie, Bernardin, François, Dittmar, Gunnar, Francescato, Elisabetta, Hewings, Simon J., Jakwerth, Constanze A., Zissler, Ulrich M., Heath, Matthew D., Ollert, Markus, Kramer, Matthias F., Hilger, Christiane, Bilò, Maria Beatrice, Schmidt-Weber, Carsten B., and Blank, Simon
- Subjects
- *
ALLERGENS , *SNAKE venom , *VENOM , *ALLERGENIC extracts , *WASPS , *IMMUNOTHERAPY , *LIQUID chromatography-mass spectrometry , *VENOM hypersensitivity - Abstract
Allergy to Polistes dominula (European paper wasp) venom is of particular relevance in Southern Europe, potentially becoming a threat in other regions in the near future, and can be effectively cured by venom immunotherapy (VIT). As allergen content in extracts may vary and have an impact on diagnostic and therapeutic approaches, the aim was to compare five therapeutic preparations for VIT of P. dominula venom allergy available in Spain. Products from five different suppliers were analyzed by SDS-PAGE and LC-MS/MS and compared with a reference venom sample. Three products with P. dominula venom and one product with a venom mixture of American Polistes species showed a comparable band pattern in SDS-PAGE as the reference sample and the bands of the major allergens phospholipase A1 and antigen 5 were assignable. The other product, which consists of a mixture of American Polistes species, exhibited the typical band pattern in one, but not in another sample from a second batch. All annotated P. dominula allergens were detected at comparable levels in LC-MS/MS analysis of products containing P. dominula venom. Due to a lack of genomic information on the American Polistes species, the remaining products were not analyzed by this method. The major Polistes allergens were present in comparable amounts in the majority, but not in all investigated samples of venom preparations for VIT of P. dominula venom allergy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Get £5 off when you spend £30 at Holland & Barrett with your paper this weekend; Keep the winter bugs at bay with this great offer!
- Subjects
Holland and Barrett ,Immunotherapy ,General interest ,News, opinion and commentary - Abstract
Byline: By, Chloe Robinson Stave off the cold and flu this winter by boosting your immune system with our money saving offer from Holland & Barrett. You will save £5 [...]
- Published
- 2023
28. Get £5 off when you spend £30 at Holland and Barrett with your paper this weekend; Keep the winter bugs at bay with this great offer!
- Subjects
Immunotherapy ,General interest ,News, opinion and commentary - Abstract
Byline: By, Chloe Robinson Stave off the cold and flu this winter by boosting your immune system with our money saving offer from Holland and Barrett. You will save £5 [...]
- Published
- 2023
29. Get £5 off when you spend £30 at Holland & Barrett with your paper this weekend; Keep the winter bugs at bay with this great offer!
- Subjects
Holland and Barrett ,Immunotherapy ,General interest ,News, opinion and commentary - Abstract
Byline: By, Chloe Robinson Stave off the cold and flu this winter by boosting your immune system with our money saving offer from Holland & Barrett. You will save £5 [...]
- Published
- 2023
30. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper
- Author
-
Fabio Gomes, Nicolò Matteo Luca Battisti, Tiana Kordbacheh, Andrea Luciani, Alastair Greystoke, M. Kiderlen, Melisa L. Wong, and Radiotherapy
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Immunosenescence ,medicine.medical_treatment ,Antineoplastic Agents ,Review Article ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Lung cancer ,Immune Checkpoint Inhibitors ,030304 developmental biology ,0303 health sciences ,Chemotherapy ,Clinical Trials as Topic ,business.industry ,Immunotherapy ,Radioimmunotherapy ,medicine.disease ,Clinical trial ,Radiation therapy ,Geriatric oncology ,030220 oncology & carcinogenesis ,Position paper ,Non small cell ,business ,Non-small-cell lung cancer - Abstract
Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.
- Published
- 2020
31. AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper.
- Author
-
Bergmann, Christoph, Poli, Aurélie, Agache, Ioana, Bianchini, Rodolfo, Bax, Heather J., Castells, Mariana, Crescioli, Silvia, Dombrowicz, David, Ferastraoaru, Denisa, Fiebiger, Edda, Gould, Hannah J., Hartmann, Karin, Izquierdo, Elena, Jordakieva, Galateja, Josephs, Debra H., Jutel, Marek, Levi‐Schaffer, Francesca, de las Vecillas, Leticia, Lotze, Michael T., and Osborn, Gabriel
- Subjects
- *
CLINICAL immunology , *ALLERGIES , *AUTOIMMUNE diseases , *IMMUNE response , *HAZARDS , *DISEASE risk factors - Abstract
The immune system interacts with many nominal 'danger' signals, endogenous danger‐associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)‐associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti‐cancer immune and targeted therapies. Cross‐disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Diagnostic therapeutic care pathway for pediatric food allergies and intolerances in Italy: a joint position paper by the Italian Society for Pediatric Gastroenterology Hepatology and Nutrition (SIGENP) and the Italian Society for Pediatric Allergy and Immunology (SIAIP)
- Author
-
Berni Canani, Roberto, Caffarelli, Carlo, Calvani, Mauro, Martelli, Alberto, Carucci, Laura, Cozzolino, Tommaso, Alvisi, Patrizia, Agostoni, Carlo, Lionetti, Paolo, and Marseglia, Gian Luigi
- Subjects
- *
TREATMENT of food intolerance , *DIAGNOSIS of food allergies , *SKIN tests , *FOOD intolerance , *PEDIATRICS , *HEALTH care teams , *PROFESSIONAL associations , *FOOD allergy , *IMMUNOTHERAPY , *SYMPTOMS , *CHILDREN - Abstract
Epidemiologic data suggest an increased prevalence of pediatric food allergies and intolerances (FAIs) during the last decades. This changing scenario has led to an increase in the overall healthcare costs, due to a growing demand for diagnostic and treatment services. There is the need to establish Evidence-based practices for diagnostic and therapeutic intervention that could be adopted in the context of public health policies for FAIs are needed. This joint position paper has been prepared by a group of experts in pediatric gastroenterology, allergy and nutrition from the Italian Society for Pediatric Gastroenterology Hepatology and Nutrition (SIGENP) and the Italian Society for Pediatric Allergy and Immunology (SIAIP). The paper is focused on the Diagnostic Therapeutic Care Pathway (DTCP) for pediatric FAIs in Italy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Transgene and BioInvent Joint Paper on BT-001 Wins JITC 'Best Oncolytic and Local Immunotherapy Paper' Award for 2022
- Subjects
Euronext Paris S.A. -- Achievements and awards ,Biological products industry -- Achievements and awards ,Viral antibodies ,Immunotherapy ,Antibodies ,Business ,Business, international - Abstract
Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in [...]
- Published
- 2022
34. Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer.
- Author
-
Hu Q, Wang S, Ma L, Sun Z, Liu Z, Deng S, and Zhou J
- Subjects
- Humans, SARS-CoV-2, Radiation Pneumonitis diagnostic imaging, Radiation Pneumonitis etiology, Lung Neoplasms drug therapy, Lung Neoplasms diagnostic imaging, Lung Neoplasms immunology, Lung Neoplasms pathology, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Pneumonia diagnostic imaging, Pneumonia chemically induced, Pneumonia etiology, Immunotherapy adverse effects, Immunotherapy methods, COVID-19 immunology, Tomography, X-Ray Computed methods
- Abstract
Immune checkpoint inhibitors (ICIs) therapy have revolutionized advanced lung cancer care. Interestingly, the host responses for patients received ICIs therapy are distinguishing from those with cytotoxic drugs, showing potential initial transient worsening of disease burden, pseudoprogression and delayed time to treatment response. Thus, a new imaging criterion to evaluate the response for immunotherapy should be developed. ICIs treatment is associated with unique adverse events, including potential life-threatening immune checkpoint inhibitor-related pneumonitis (ICI-pneumonitis) if treated patients are not managed promptly. Currently, the diagnosis and clinical management of ICI-pneumonitis remain challenging. As the clinical manifestation is often nonspecific, computed tomography (CT) scan and X-ray films play important roles in diagnosis and triage. This article reviews the complications of immunotherapy in lung cancer and illustrates various radiologic patterns of ICI-pneumonitis. Additionally, it is tried to differentiate ICI-pneumonitis from other pulmonary pathologies common to lung cancer such as radiation pneumonitis, bacterial pneumonia and coronavirus disease of 2019 (COVID-19) infection in recent months. Maybe it is challenging to distinguish radiologically but clinical presentation may help., (© 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
35. Clinical outcome and component-specific antibody levels in egg allergic children after lightened oral immunotherapy.
- Author
-
Koffert A, Liippo J, Löyttyniemi E, and Savolainen J
- Subjects
- Child, Humans, Powders, Immunoglobulin A, Immunoglobulin E, Immunoglobulin G, Immunotherapy, Eggs
- Abstract
Objective: To evaluate the clinical outcome of lightened version of egg oral immunotherapy (OIT) and to analyze egg allergen component-specific antibody levels during short up-dosing with egg white powder and maintenance by egg in daily diet., Patients and Methods: Eighteen egg-allergic children received egg powder with short up--dosing and they maintained tolerance using egg in daily diet. Seventeen egg-allergic children served as a control group. Component-resolved analysis of serum immunoglobulin E (IgE), IgA1, IgA2, and IgG4 levels were determined at inclusion, after up-dosing and after 1 year of immunotherapy. Skin-prick tests were performed at inclusion and after 1 year of therapy., Results: All 18 patients in the egg OIT group were successfully desensitized. Desensitization was achieved on average in 4.5 months. In the control group, only two children tolerated egg in oral food challenge after 1 year. Of the measured immune markers, smaller wheal diameters in skin-prick testing, reduction in component-specific IgE levels, and increase in component-specific IgA1, IgA2, and IgG4 levels were associated with desensitization., Conclusion: A lightened egg OIT is effective and safe in children with egg allergy. Increase in all egg component-specific IgA1, IgA2 and IgG4 levels and decrease in all egg component--specific IgE levels were observed after 12 months of OIT.
- Published
- 2024
- Full Text
- View/download PDF
36. Nature Paper from PACT Pharma and UCLA Highlights How Patients with Cancer Respond Differently to Anti-PD-1 Therapy
- Subjects
T cells ,Cancer patients -- Care and treatment ,Immunotherapy ,Cancer -- Care and treatment ,Tumor antigens ,Business ,News, opinion and commentary - Abstract
All Patients' Immune Systems Were Capable of Recognizing Mutations Within Their Tumors Patients Who Benefitted from Treatment Mounted Diverse Immune Responses Against a Small Number of Cancer-Specific Targets; Non-Responders Showed [...]
- Published
- 2023
37. In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan--An EAACI position paper
- Author
-
Hans Jürgen Hoffmann, Matteo Bonini, Victoria Cardona, Markus Ollert, Oliver Pfaar, Pascal Demoly, Peter Schmid-Grendelmeier, Mohamed H. Shamji, Vera Mahler, Helen A. Brough, Peter Hellings, Torsten Zuberbier, Karin Hoffmann-Sommergruber, Sten Dreborg, Carsten B. Schmidt-Weber, Marek Jutel, Stefan Vieths, Oscar Palomares, Ludger Klimek, Ayse Fusun Kalpaklioglu, Sergio Bonini, Andreas Bonertz, Antonella Muraro, Jean Bousquet, Ioana Agache, Todor A. Popov, Ear, Nose and Throat, KKÜ, University of Zurich, and Klimek, Ludger
- Subjects
0301 basic medicine ,Allergy ,IMPACT ,CHILDREN ,allergen provocation test ,Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,GUIDELINES ,0302 clinical medicine ,immune system diseases ,European Pharmacopoeia ,Immunology and Allergy ,Reimbursement ,10177 Dermatology Clinic ,Diagnostic test ,respiratory system ,marketing authorization ,regulatory framework ,skin prick test ,skin test allergens ,Call to action ,Europe ,DISEASES ,Action plan ,2723 Immunology and Allergy ,Skin prick test ,Skin test allergens ,allergen challenge test ,reimbursement ,Medical emergency ,Life Sciences & Biomedicine ,Immunology ,Allergen Provocation Test ,Marketing Authorization ,Regulatory Framework ,Skin Prick Test ,Skin Test Allergens ,610 Medicine & health ,Marketing authorization ,LEGISLATION ,03 medical and health sciences ,Pharmacovigilance ,Hypersensitivity ,medicine ,Humans ,IMMUNOTHERAPY ,PROVOCATION ,Skin Tests ,2403 Immunology ,Science & Technology ,Diagnostic Tests, Routine ,AVAILABILITY ,Allergens ,medicine.disease ,respiratory tract diseases ,030104 developmental biology ,030228 respiratory system ,Position paper ,Allergists ,Business - Abstract
Bonertz, Andreas/0000-0002-6846-9265; Brough, Helen/0000-0001-7203-0813; Hoffmann, Hans Jurgen/0000-0002-6743-7931; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Schmid-Grendelmeier, Peter/0000-0003-3215-3370 WOS:000569864500002 PubMed: 32306414 Diagnostic allergens are defined as medicinal products in the EU. Marketing authorization by national authorities is necessary; however, diagnostic allergens are not homogeneously regulated in different EU member states. Allergen manufacturers argue with increasing costs forcing them to continuously reduce the diagnostic allergen portfolios offered to allergists. In contrast, EAACI and national European Allergy Societies see the need for the availability of a wide range of high-quality diagnostic allergens for in vivo diagnosis of IgE-mediated allergies not only covering predominant but also less frequent allergen sources. In a recent EAACI task force survey, the current practice of allergy diagnosis was shown to rely on skin tests as first option in almost 2/3 of all types of allergic diseases and in 90% regarding respiratory allergies. With the need to ensure the availability of high-quality diagnostic allergens in the EU, an action plan has been set up by EAACI to analyse the current regulatory demands in EU member states and to define possible solutions stated in this document: (a) simplification of authorization for diagnostic allergens; (b) specific regulation of special types of diagnostic allergens; (c) new models beyond the current model of homologous groups; (d) simplification of pharmacovigilance reporting; (e) reduction of regulation fees for diagnostic allergens; (f) reimbursement for diagnostic allergens. Joining forces of allergists, manufacturers and authorities are of high importance to ensure remaining relevant allergens in the EU markets to facilitate a sustainable and comprehensive service for the diagnosis and treatment of allergic diseases.
- Published
- 2020
38. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
- Author
-
Bastiaannet, Esther, Battisti, Nicolò, Loh, Kah Poh, de Glas, Nienke, Soto-Perez-de-Celis, Enrique, Baldini, Capucine, Kapiteijn, Ellen, and Lichtman, Stuart
- Abstract
Malignant melanoma is an aggressive cancer associated with a poor prognosis in patients with metastatic disease. As in many other cancers, the incidence of melanoma rises with age; and combined with the longer life expectancy, this led to an increasing prevalence of melanoma in the older population. Recently, immune checkpoint inhibitors significantly improved the treatment of melanoma given their efficacy and tolerability profile. Two major classes of agents include the anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors, such as ipilimumab, and the anti-programmed death-ligand 1 (PD-1) inhibitors, such as nivolumab and pembrolizumab. Treatment of metastatic disease with immune checkpoint inhibitors demonstrated improved efficacy and better safety profiles compared to cytotoxic drugs and appears to be an attractive treatment option. Nevertheless, there is a need for tools designed to better predict which older patients will benefit from its use and who will experience toxicities related to the treatment. Current data do not show a major increase in toxicity rates in older patients. However, patients above 75 are often under-represented and those who are included are not representative of the general population of older patients, thereby also stressing the need for real-life data. Ongoing research is aiming at maximizing the potential treatment efficacy and developing novel immune-targeting modalities. Future studies should include older patients and assess geriatric domains in these older patients to better guide decision-making. This review discusses published clinical trials and where known, the efficacy and toxicity in older patients. Moreover, the clinical implications and future perspectives are discussed, with current recommendations for older patients, management of toxicities, and a proposal for an initial approach to the treatment of older patients with metastatic melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. New ACAAI position paper examines safety of receiving live vaccines while on dupilumab.
- Abstract
A new position paper from the American College of Allergy, Asthma & Immunology (ACAAI) examines the safety of administering live vaccines to patients currently being treated with dupilumab, a biologic therapy for allergic conditions. The paper concludes that it is not necessary to stop treatment with dupilumab to give live vaccines, but the decision should be made in consultation between the physician and the patient/parent. The goal of the review was to ensure that patients receiving dupilumab can also receive the full protection of recommended vaccines. The panel recommends shared decision-making between doctors and patients/parents regarding the timing and administration of live vaccines while on dupilumab. [Extracted from the article]
- Published
- 2024
40. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper.
- Author
-
Pfaar, Oliver, Agache, Ioana, Bergmann, Karl‐Christian, Bindslev‐Jensen, Carsten, Bousquet, Jean, Creticos, Peter S., Devillier, Philippe, Durham, Stephen R., Hellings, Peter, Kaul, Susanne, Kleine‐Tebbe, Jörg, Klimek, Ludger, Jacobsen, Lars, Jutel, Marek, Muraro, Antonella, Papadopoulos, Nikolaos G., Rief, Winfried, Scadding, Glenis K., Schedlowski, Manfred, and Shamji, Mohamed H.
- Subjects
- *
PLACEBOS , *TASK forces , *ALLERGENS , *CLINICAL trials , *IMMUNOTHERAPY - Abstract
The placebo (Latin "I will please") effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients' expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double‐blind, placebo‐controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Mission Bio's Tapestri® Platform Used to Identify Hidden HIV-infected Cells in Nature Paper
- Subjects
HIV (Viruses) -- Diagnosis ,T cells ,Immunotherapy ,HIV patients ,HIV infection -- Diagnosis ,Health ,Harvard University. Harvard Medical School - Abstract
2023 JAN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a new publication [...]
- Published
- 2023
42. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
- Author
-
Seok Jin Kim, Dok Hyun Yoon, Deok Hwan Yang, Bing Xu, Koji Izutsu, Lim Soon Thye, Tong Yu Lin, Junning Cao, Tsai Yun Chen, Won Seog Kim, and Yok-Lam Kwong
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Asia ,medicine.medical_treatment ,Antineoplastic Agents ,Review ,Lymphoma, Mantle-Cell ,Hematopoietic stem cell transplantation ,Disease ,Guidelines ,lcsh:RC254-282 ,chemistry.chemical_compound ,Maintenance therapy ,Chemoimmunotherapy ,Internal medicine ,medicine ,Humans ,Molecular Biology ,Mantle cell lymphoma ,business.industry ,lcsh:RC633-647.5 ,Hematopoietic Stem Cell Transplantation ,Disease Management ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Lymphoma ,Radiation therapy ,Treatment ,chemistry ,Ibrutinib ,Immunotherapy ,business - Abstract
Background Mantle cell lymphoma (MCL) is a B cell malignancy that can be aggressive and with a poor prognosis; the clinical course is heterogeneous. The epidemiology of MCL in Asia is not well documented but appears to comprise 2–6% of all lymphoma cases based on available data, with variation observed between countries. Although international guidelines are available for the treatment of MCL, there is a lack of published data or guidance on the clinical characteristics and management of MCL in patient populations from Asia. This paper aims to review the available treatment and, where clinical gaps exist, provide expert consensus from the Asian Lymphoma Study Group (ALSG) on appropriate MCL management in Asia. Body Management strategies for MCL are patient- and disease stage-specific and aim to achieve balance between efficacy outcomes and toxicity. For asymptomatic patients with clearly indolent disease, observation may be an appropriate strategy. For stage I/II disease, following international guidelines is appropriate, which include either a short course of conventional chemotherapy followed by consolidated radiotherapy, less aggressive chemotherapy regimens, or a combination of these approaches. For advanced disease, the approach is based on the age and fitness of the patient. For young, fit patients, the current practice for induction therapy differs across Asia, with cytarabine having an important role in this setting. Hematopoietic stem cell transplantation (HSCT) may be justified in selected patients because of the high relapse risk. In elderly patients, specific chemoimmunotherapy regimens available in each country/region are a treatment option. For maintenance therapy after first-line treatment, the choice of approach should be individualized, with cost being an important consideration within Asia. For relapsed/refractory disease, ibrutinib should be considered as well as other follow-on compounds, if available. Conclusion Asian patient-specific data for the treatment of MCL are lacking, and the availability of treatment options differs between country/region within Asia. Therefore, there is no clear one-size-fits-all approach and further investigation on the most appropriate sequence of treatment that should be considered for this heterogeneous disease.
- Published
- 2020
43. Candidacy for extracorporeal life support (ECLS) in children after hematopoietic cell transplantation (HCT): a position paper from the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network’s Hematopoietic Cell Transplant and Cancer Immunotherapy (CI) subgroup
- Author
-
Zinter, Matt S., McArthur, Jennifer, Duncan, Christine, Adams, Roberta, Kreml, Erin, Dalton, Heidi, Abdel-Azim, Hisham, Rowan, Courtney M., Gertz, Shira J., Mahadeo, Kris M., Randolph, Adrienne G., Rajapreyar, Prakadeshwari, Steiner, Marie E., and Lehmann, Leslie
- Subjects
Extracorporeal Membrane Oxygenation ,Critical Illness ,Neoplasms ,Sepsis ,Acute Lung Injury ,Hematopoietic Stem Cell Transplantation ,Humans ,Immunotherapy ,Child ,Article - Abstract
The last decade has seen improved outcomes for children requiring extracorporeal life support as well as for children undergoing hematopoietic cell transplantation. Thus, given the historically poor survival of hematopoietic cell transplantation patients using extracorporeal life support, the Pediatric Acute Lung Injury and Sepsis Investigators' hematopoietic cell transplantation and cancer immunotherapy subgroup aimed to characterize the utility of extracorporeal life support in facilitating recovery from critical cardiorespiratory illnesses in pediatric hematopoietic cell transplantation patients.All available published data were identified using a set of PubMed search terms for pediatric extracorporeal life support and hematopoietic cell transplantation.All articles that provided original reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support were included. Sixty-four manuscripts met search criteria. Twenty-four were included as primary reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support (11 were single case reports, four single institution case series, two multi-institution case series, and seven registry reports from Extracorporeal Life Support Organization, Pediatric Heath Information System, and Virtual Pediatric Systems).All 24 articles were reviewed by first and last authors and a spread sheet was constructed including sample size, potential biases, and conclusions.Discussions regarding incorporation of available evidence into our clinical practice were held at biannual meetings, as well as through email and virtual meetings. An expert consensus was determined through these discussions and confirmed through a modified Delphi process.Extracorporeal life support in hematopoietic cell transplantation patients is being used with increasing frequency and potentially improving survival. The Pediatric Acute Lung Injury and Sepsis Investigators hematopoietic cell transplantation-cancer immunotherapy subgroup has developed a framework to guide physicians in decision-making surrounding extracorporeal life support candidacy in pediatric hematopoietic cell transplantation patients. In addition to standard extracorporeal life support considerations, candidacy in the hematopoietic cell transplantation population should consider the following six factors in order of consensus agreement: 1) patient comorbidities; 2) underlying disease necessitating hematopoietic cell transplantation; 3) hematopoietic cell transplantation toxicities, 4) family and patient desires for goals of care; 5) hematopoietic cell transplantation preparatory regimen; and 6) graft characteristics. Although risk assessment may be individualized, data are currently insufficient to clearly delineate ideal candidacy. Therefore, we urge the onco-critical care community to collaborate and capture data to provide better evidence to guide physicians' decision-making in the future.
- Published
- 2022
44. Cancer Cell Paper Identifies 'Avidity Enhancement' As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia
- Subjects
T cells ,Antineoplastic agents ,Immunotherapy ,Cancer -- Care and treatment ,Antimitotic agents ,General interest ,News, opinion and commentary - Abstract
AMSTERDAM: LUMICKS has issued the following news release: LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in [...]
- Published
- 2022
45. Cancer Cell Paper Identifies 'Avidity Enhancement' As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia
- Subjects
T cells ,Antineoplastic agents ,Immunotherapy ,Cancer -- Care and treatment ,Antimitotic agents ,Business ,News, opinion and commentary - Abstract
Research Revealed Through Cell Avidity Measurement Demonstrates Superior Tumor Clearance In Vivo Due To 'Avidity Enhancement' AMSTERDAM, May 24, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that [...]
- Published
- 2022
46. Systemic treatment of hepatocellular carcinoma: An EASL position paper.
- Author
-
Bruix, Jordi, Chan, Stephen L., Galle, Peter R., Rimassa, Lorenza, and Sangro, Bruno
- Subjects
- *
HEPATOCELLULAR carcinoma , *MEDICAL personnel , *IMMUNE checkpoint inhibitors , *NIVOLUMAB , *ATEZOLIZUMAB - Abstract
The last 5 years have witnessed relevant advances in the systemic treatment of hepatocellular carcinoma. New data have emerged since the development of the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma in 2018. Drugs licensed in some countries now include 4 oral multi-tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), 1 anti-angiogenic antibody (ramucirumab) and 4 immune checkpoint inhibitors, alone or in combination (atezolizumab in combination with bevacizumab, ipilimumab in combination with nivolumab, nivolumab and pembrolizumab in monotherapy). Prolonged survival in excess of 2 years can be expected in most patients with sensitive tumours and well-preserved liver function that renders them fit for sequential therapies. With different choices available in any given setting, the robustness of the evidence of efficacy and a correct matching of the safety profile of a given agent with patient characteristics and preferences are key in making sound therapeutic decisions. The recommendations in this document amend the previous EASL Clinical Practice Guidelines and aim to help clinicians provide the best possible care for patients today. In view of several ongoing and promising trials, further advances in systemic therapy of hepatocellular carcinoma are foreseen in the near future and these recommendations will have to be updated regularly. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. A novel method for precise detection of allergen‐specific IgE via immobilizing His‐tagged allergens to paper‐based device.
- Author
-
Cao, Mengda, Han, Xisi, Lu, Chen, Wang, Yujie, Xu, Zhiqiang, Wang, Shuangxi, Zhou, Bicong, Zhang, Chengwu, Yu, Changmin, Li, Lin, and Wei, Ji‐Fu
- Subjects
- *
ALLERGENS , *SUBLINGUAL immunotherapy , *IMMUNOTHERAPY - Abstract
A novel method for precise detection of allergen-specific IgE via immobilizing His-tagged allergens to paper-based device To the Editor, Allergic diseases are characterized by elevated specific IgE (sIgE) serum levels against certain allergens.1,2 Thus, the fast and precise detection of sIgE is necessary for the diagnosis of allergic diseases. The features of this strategy for allergen immobilization were highlighted with strong and specific binding site, particularly the preservation of sIgE-binding activity without covering any IgE-binding epitopes of allergens (Figure 1B). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
48. Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507).
- Author
-
Tempo, Jake, Bolton, Damien, and O'Callaghan, Michael
- Subjects
TRANSITIONAL cell carcinoma ,BCG immunotherapy ,UROLOGY ,IMMUNOTHERAPY ,ONCOLOGY - Abstract
The South West Oncology Group's 2000 randomised-control trial investigated the addition of maintenance intravesical bacillus Calmette-Guerin (BCG) to non-muscle invasive urothelial carcinoma (NMIUC) treatment. The results were published when the efficacy of BCG immunotherapy maintenance was unclear. Randomisation produced two arms, each containing 192 patients assessed to be at high risk of recurrence following induction BCG therapy for NMIUC. The treatment arm went on to receive three successive weekly intravesical and percutaneous BCG administrations at three months, six months and then six monthly for three years from the start of induction therapy. Recurrence free-survival (RFS), was higher in the maintenance arm with 41% (95%CI 35–49) RFS at five years in the control arm and 60% RFS (53–67 95% CI) in the maintenance arm (p < 0.0001). Only 16% of patients in the treatment arm received all of the scheduled maintenance courses of BCG. The study's seminal results correlate with contemporary systematic review and have guided international guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Characterization of New Allergens from the Venom of the European Paper Wasp Polistes dominula
- Author
-
Clara San Bartolome, Federico De La Roca Pinzón, Michael Dittmar, Maria Beatrice Bilò, Mariona Pascal, Ulf Darsow, Christiane Hilger, Simon Blank, Carsten B. Schmidt-Weber, Tilo Biedermann, Markus Ollert, Sebastian Waldherr, Bernadette Eberlein, and Johannes Grosch
- Subjects
Allergy ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,Allergen ,Allergen Cross-reactivity ,Hymenoptera Venom Allergy ,Phospholipase A2 ,Polistes Dominula ,Venom ,Context (language use) ,Toxicology ,Polistes dominula ,medicine.disease_cause ,complex mixtures ,allergen cross-reactivity ,medicine ,Sensitization ,biology ,Allergen cross-reactivity ,Immunotherapy ,biology.organism_classification ,medicine.disease ,Sting ,medicine.anatomical_structure ,Immunology ,Medicine ,phospholipase A2 ,Hymenoptera venom allergy ,allergen - Abstract
Discriminating Polistes dominula and Vespula spp. venom allergy is of growing importance worldwide, as systemic reactions to either species’ sting can lead to severe outcomes. Administering the correct allergen-specific immunotherapy is therefore a prerequisite to ensure the safety and health of venom-allergic patients. Component-resolved diagnostics of Hymenoptera venom allergy might be improved by adding additional allergens to the diagnostic allergen panel. Therefore, three potential new allergens from P. dominula venom—immune responsive protein 30 (IRP30), vascular endothelial growth factor C (VEGF C) and phospholipase A2 (PLA2)—were cloned, recombinantly produced and biochemically characterized. Sera sIgE titers of Hymenoptera venom-allergic patients were measured in vitro to assess the allergenicity and potential cross-reactivity of the venom proteins. IRP30 and VEGF C were classified as minor allergens, as sensitization rates lay around 20–40%. About 50% of P. dominula venom-allergic patients had measurable sIgE titers directed against PLA2 from P. dominula venom. Interestingly, PLA2 was unable to activate basophils of allergic patients, questioning its role in the context of clinically relevant sensitization. Although the obtained results hint to a questionable benefit of the characterized P. dominula venom proteins for improved diagnosis of venom-allergic patients, they can contribute to a deeper understanding of the molecular mechanisms of Hymenoptera venoms and to the identification of factors that determine the allergenic potential of proteins.
- Published
- 2021
50. The complementarity of DDR, nucleic acids and anti-tumour immunity.
- Author
-
Kornepati AVR, Rogers CM, Sung P, and Curiel TJ
- Subjects
- Humans, Antigens, Neoplasm immunology, Antigens, Neoplasm metabolism, DNA Repair, DNA Replication, Mutation, Biomarkers, Tumor, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, DNA Damage, Immunotherapy methods, Immunotherapy trends, Neoplasms genetics, Neoplasms immunology, Neoplasms metabolism, Neoplasms therapy, Nucleic Acids metabolism, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use
- Abstract
Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore, only a minority of patients with cancer benefit from ICB, and there is a lack of fully informative treatment response biomarkers. Selectively exploiting defects in DNA damage repair is also a standard treatment for cancer, spurred by enhanced understanding of the DNA damage response (DDR). DDR and ICB are closely linked-faulty DDR produces immunogenic cancer neoantigens that can increase the efficacy of ICB therapy, and tumour mutational burden is a good but imperfect biomarker for the response to ICB. DDR studies in ICB efficacy initially focused on contributions to neoantigen burden. However, a growing body of evidence suggests that ICB efficacy is complicated by the immunogenic effects of nucleic acids generated from exogenous DNA damage or endogenous processes such as DNA replication. Chemotherapy, radiation, or selective DDR inhibitors (such as PARP inhibitors) can generate aberrant nucleic acids to induce tumour immunogenicity independently of neoantigens. Independent of their functions in immunity, targets of immunotherapy such as cyclic GMP-AMP synthase (cGAS) or PD-L1 can crosstalk with DDR or the DNA repair machinery to influence the response to DNA-damaging agents. Here we review the rapidly evolving, multifaceted interfaces between DDR, nucleic acid immunogenicity and immunotherapy efficacy, focusing on ICB. Understanding these interrelated processes could explain ICB treatment failures and reveal novel exploitable therapeutic vulnerabilities in cancers. We conclude by addressing major unanswered questions and new research directions., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.